The rising impact of angiogenesis research

Arjan W Griffioen1, Andrew C Dudley2

  • 1Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. a.griffioen@amsterdamumc.nl.

Angiogenesis
|July 26, 2022
PubMed

Insights

Targeting angiogenesis, the formation of new blood vessels, is crucial for treating cancer and other non-malignant diseases like ischemic conditions. Recent research shows reprogramming vasculature enhances immunotherapy, highlighting angiogenesis

Area of Science:

  • * Angiogenesis research extends beyond oncology to non-malignant diseases.
  • * Therapeutic applications span ophthalmology, cardiology, and gynecology.

Background:

  • * Inhibiting pathological angiogenesis is key in oncology.
  • * Stimulators of angiogenesis treat ischemic diseases.
  • * Inhibitors are used judiciously to reprogram vasculature for immunotherapy.

Discussion:

  • * Angiogenesis targeting is a well-established therapeutic approach.
  • * Increasing citations reflect the growing impact of angiogenesis research.
  • * Diverse conditions benefit from modulating blood vessel formation.

Key Insights:

  • * Angiogenesis research has expanded to non-malignant conditions.
  • * Vascular reprogramming is a novel strategy for immunotherapy enhancement.
  • * Targeting angiogenesis offers a tractable approach for various diseases.

Outlook:

  • * Continued exploration of angiogenesis modulators for diverse therapeutic areas.
  • * Integration of angiogenesis strategies with immunotherapy.
  • * Further research into reprogramming vasculature for improved treatment outcomes.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
7.5K